AZ-EDGIO
25.4.2024 14:01:25 CEST | Business Wire | Press release
Edgio, the platform of choice for security, speed and simplicity at the edge, today announced the release of its Client-Side Protection solution. Designed to monitor scripts and APIs on the browser-side to prevent malicious code from exfiltrating sensitive customer data, Edgio Client-Side Protection allows teams to gain full visibility on client-side vulnerabilities, achieve full control over all first- and third-party resources and maintain the latest compliance requirements.
Payment Card Industry (PCI) Data Security Standard (DSS) v4.0 represents the latest global standards for protecting payment data against sophisticated cyber attacks. PCI DSS v4.0 reflects the latest needs of the payments industry as threats evolve, including damaging Magecart attacks, a type of digital credit card skimming. With Magecart skimmers spotted in over 2 million websites, organizations must prioritize proactively protecting customer data based on a comprehensive understanding of the scripts and external APIs that execute on customer devices. With Edgio Client-Side Protection, organizations handling payment data will be well positioned to gain a competitive edge by adopting client-side security controls ahead of the PCI DSS 4.0’s March 2025 deadline.
Edgio Client-Side Protection enables organizations to secure critical customer data and streamline compliance workflows. Through continuous discovery and monitoring, the solution inventories all browser-side resources and API calls, both first and third party, providing simplified management from an intuitive interface to mitigate any malicious scripts. Edgio’s solution is unique in offering a continuous dual execution mode that allows teams to test multiple content security policies for their website in audit mode, while enforcing existing client-side protection directives in production mode. This ability gives teams confidence to push out new policies quickly without risk of impairing the core functionality of the application.
“Edgio Client-Side Protection is proud to offer a full inventory and real-time reporting of all client-side scripts allowing security teams to investigate treats with unprecedented ease and power,” said Edgio CTO Ajay Kapur. “Edgio Client-Side Protection supports the latest compliance requirements and addresses one of the biggest threats to ecommerce websites. It is the most recent addition to Edgio’s holistic, multi-layer Web Application & API Protection (WAAP) solution, which provides comprehensive protection from data breaches in real-time.”
Client-Side Protection is a key component of Edgio’s holistic Web Application and API Protection (WAAP), a multi-layer security solution built on a global network with over 250 Tbps capacity and over 300 points of presence (PoPs). Edgio WAAP offers integrated components for full defense-in-depth including Web Application Firewall (WAF), Advanced Bot Management, Layer 3-7 DDoS Protection, and API Security.
To learn more, visit Edgio’s website.
About Edgio
Edgio (NASDAQ: EGIO) helps companies deliver online experiences and content faster, safer, and with more control. Our developer-friendly, global edge network, combined with our fully integrated application and media solutions, provides a single platform for the delivery of high-performing, secure web properties and streaming content. Through this fully integrated platform and end-to-end edge services, companies can deliver content quicker and more securely, boosting revenue, accelerating teams, while reducing costs. To learn more, visit edg.io and follow us on Twitter, LinkedIn and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240425316958/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom